Table 1.

The median time (y) to oral cancer development and OCF rates at years 5 and 10 for all patients (n = 145)

VariableLevelNEventMedian (95% CI)OCF rate at 5 y (95% CI)OCF rate at 10 y (95% CI)P*
All patients14535NA0.8 (0.74-0.87)0.72 (0.65-0.81)
SexFemale6816NA0.78 (0.69-0.89)0.73 (0.62-0.86)0.843
Male7719NA0.82 (0.74-0.92)0.72 (0.62-0.84)
RaceOther163NA0.85 (0.67-1)0.75 (0.54-1)0.719
White12932NA0.8 (0.73-0.87)0.72 (0.64-0.81)
Histologic statusHyperplasia9719NA0.85 (0.78-0.92)0.78 (0.7-0.88)0.064
Mild dysplasia3711NA (6.65-NA)0.74 (0.61-0.9)0.65 (0.5-0.85)
Moderate/severe dysplasia1156.67 (1.85-NA)0.61 (0.38-1)0.46 (0.22-0.97)
Treatment arm13cRA7318NA0.78 (0.69-0.89)0.72 (0.61-0.84)0.565
BC + RP408NA0.84 (0.73-0.97)0.8 (0.68-0.95)
RP329NA (6.65-NA)0.8 (0.67-0.96)
Smoking historyCurrent517NA0.87 (0.78-0.97)0.83 (0.72-0.96)0.099
Former5820NA (6.65-NA)0.75 (0.64-0.87)0.62 (0.5-0.78)
Never368NA0.8 (0.68-0.94)0.76 (0.63-0.92)
Alcohol historyCurrent8018NA0.84 (0.76-0.93)0.74 (0.64-0.86)0.783
Former195NA (6.21-NA)0.78 (0.61-1)0.68 (0.48-0.98)
Never4612NA0.75 (0.63-0.89)0.72 (0.6-0.87)
EGFR protein expressionLow426NA0.89 (0.8-1)0.82 (0.69-0.96)0.105
High10329NA (10.7-NA)0.77 (0.69-0.86)0.69 (0.6-0.8)

Abbreviation: NA, not applicable.

  • *P values are from the log-rank test (univariate analysis).

  • Semiquantitative evaluation; EGFR low: score 0-1 at immunohistochemistry; EGFR high: score 2-3 at immunohistochemistry.